Published in J Clin Oncol on July 13, 2009
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst (2010) 3.30
Phase III clinical trials that integrate treatment and biomarker evaluation. J Clin Oncol (2013) 2.15
Personalized medicine in oncology: the future is now. Nat Rev Drug Discov (2010) 1.91
Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol (2010) 1.87
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. Analyst (2010) 1.73
Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 1.67
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
Personalized medicine using DNA biomarkers: a review. Hum Genet (2012) 1.49
Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol (2013) 1.49
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol (2010) 1.42
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res (2011) 1.32
Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol (2011) 1.31
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist (2011) 1.30
New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev (2012) 1.28
Predictive biomarker validation in practice: lessons from real trials. Clin Trials (2010) 1.24
Patient-centric trials for therapeutic development in precision oncology. Nature (2015) 1.14
Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol (2010) 1.12
The ethical use of mandatory research biopsies. Nat Rev Clin Oncol (2011) 1.11
Translating biomarkers to clinical practice. Mol Psychiatry (2011) 1.09
Adaptive enrichment designs for clinical trials. Biostatistics (2013) 1.08
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer (2015) 1.07
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist (2011) 1.02
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Ont Health Technol Assess Ser (2010) 1.01
Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01
Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res (2012) 1.00
Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov (2011) 1.00
Somatic variation and cancer: therapies lost in the mix. Hum Genet (2011) 0.99
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol (2013) 0.98
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol (2011) 0.97
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer (2012) 0.96
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology (2011) 0.95
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer. EBioMedicine (2015) 0.94
Randomized reverse marker strategy design for prospective biomarker validation. Stat Med (2014) 0.94
An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov (2011) 0.91
Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep (2013) 0.91
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One (2013) 0.90
Genotype-based clinical trials in cardiovascular disease. Nat Rev Cardiol (2015) 0.89
Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers (Basel) (2011) 0.89
Adaptive designs for subpopulation analysis optimizing utility functions. Biom J (2014) 0.89
Design of clinical trials for biomarker research in oncology. Clin Investig (Lond) (2011) 0.88
Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res (2015) 0.88
Drug-diagnostics co-development in oncology. Front Oncol (2013) 0.88
Study designs and statistical analyses for biomarker research. Sensors (Basel) (2012) 0.86
Methods and challenges in quantitative imaging biomarker development. Acad Radiol (2015) 0.85
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs. Genet Med (2014) 0.85
Genomic biomarkers for personalized medicine: development and validation in clinical studies. Comput Math Methods Med (2013) 0.84
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chin Clin Oncol (2014) 0.84
All-comers versus enrichment design strategy in phase II trials. J Thorac Oncol (2011) 0.83
Genomic advances and their impact on clinical trial design. Genome Med (2009) 0.83
Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF(V600E) in Patients with Lymph Node-Positive Colon Cancer. Curr Colorectal Cancer Rep (2014) 0.83
Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs. Clin Trials (2013) 0.82
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. Clin Neuropathol (2015) 0.81
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. Br J Cancer (2014) 0.81
Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry. Anal Chem (2014) 0.81
Moving from correlative science to predictive oncology. EPMA J (2010) 0.81
Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy. Eur J Nucl Med Mol Imaging (2013) 0.81
A review of phase II trial designs for initial marker validation. Contemp Clin Trials (2013) 0.80
Assessment of reproducibility of cancer survival risk predictions across medical centers. BMC Med Res Methodol (2013) 0.80
Genomic markers to tailor treatments: waiting or initiating? Hum Genet (2011) 0.79
Adaptive clinical trial designs in oncology. Chin Clin Oncol (2014) 0.79
Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol (2017) 0.77
Designing a study to evaluate the benefit of a biomarker for selecting patient treatment. Stat Med (2015) 0.77
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups. PLoS One (2013) 0.77
Precision oncology: A new era of cancer clinical trials. Cancer Lett (2016) 0.76
Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) (2011) 0.76
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS One (2016) 0.76
Strategies for power calculations in predictive biomarker studies in survival data. Oncotarget (2016) 0.76
Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Stat Biosci (2014) 0.76
Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev (2016) 0.76
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J Pers Med (2017) 0.75
The interaction between prognostic and pharmacodynamic biomarkers. Br J Cancer (2013) 0.75
Molecular and clinical implementations of ovarian cancer mouse avatar models. Chin Clin Oncol (2015) 0.75
Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations. Int J Mol Sci (2017) 0.75
Optimal sequential enrichment designs for phase II clinical trials. Stat Med (2016) 0.75
Actionable pharmacogenetic markers for prediction and prognosis in breast cancer. EPMA J (2015) 0.75
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations. J Immunother Cancer (2016) 0.75
Stratification and partial ascertainment of biomarker value in biomarker-driven clinical trials. J Biopharm Stat (2014) 0.75
Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics (2016) 0.75
Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. Contemp Clin Trials (2014) 0.75
Adjusting for misclassification in a stratified biomarker clinical trial. Stat Med (2014) 0.75
Choosing inclusion criteria that minimize the time and cost of clinical trials. World J Methodol (2014) 0.75
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 13.39
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol (2003) 8.17
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet (2000) 5.04
Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol (2005) 4.98
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol (2008) 4.13
Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol (2008) 3.89
Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res (2004) 3.08
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin Chem (2007) 3.05
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol (2006) 2.84
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst (2007) 2.68
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat (2007) 2.07
On the efficiency of targeted clinical trials. Stat Med (2005) 1.99
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol (2008) 1.92
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res (2001) 1.74
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res (2006) 1.58
A method for testing a prespecified subgroup in clinical trials. Stat Med (2007) 1.55
Multiple testing in clinical trials. Stat Med (1991) 1.55
Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res (2008) 1.46
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer (2003) 1.43
Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics (2005) 1.43
Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics (2007) 1.38
Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat (2009) 1.30
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol (2007) 1.25
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res (2007) 1.09
Prognostic and predictive markers in cancer. Dis Markers (2004) 0.98
Cancer diagnostics: decision criteria for marker utilization in the clinic. Am J Pharmacogenomics (2005) 0.92
Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnol Annu Rev (2003) 0.92
Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs (2000) 0.92
A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med (2004) 19.45
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
The genome of woodland strawberry (Fragaria vesca). Nat Genet (2010) 5.86
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Ann Surg (2007) 5.30
Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol (2007) 4.60
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol (2009) 4.09
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol (2005) 3.88
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol (2006) 3.70
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. Biometrics (2011) 3.38
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol (2008) 2.58
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Arch Surg (2007) 2.52
Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes. J Clin Oncol (2009) 2.47
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol (2002) 2.33
Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. J Clin Oncol (2009) 2.32
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res (2008) 2.32
Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol (2004) 2.30
Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol (2005) 2.28
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
Surgeon volume does not predict outcomes in the setting of technical credentialing: results from a randomized trial in colon cancer. Ann Surg (2008) 2.19
Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res (2010) 2.18
An adaptive dose-finding design incorporating both toxicity and efficacy. Stat Med (2006) 2.16
A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery (2005) 2.10
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology (2006) 2.02
Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol (2010) 1.87
Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol (2011) 1.84
Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol (2009) 1.83
Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol (2008) 1.82
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. J Clin Oncol (2002) 1.65
Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol (2011) 1.64
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol (2013) 1.62
Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J Clin Oncol (2004) 1.61
Saturated linkage map construction in Rubus idaeus using genotyping by sequencing and genome-independent imputation. BMC Genomics (2013) 1.61
Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol (2010) 1.61
Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res (2012) 1.57
Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer (2008) 1.54
Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics (2011) 1.54
Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction. J Natl Cancer Inst (2010) 1.53
Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials. J Clin Oncol (2009) 1.53
Alternate endpoints for screening phase II studies. Clin Cancer Res (2009) 1.47
Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need? J Clin Oncol (2004) 1.46
Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics (2005) 1.43
Development of a dense SNP-based linkage map of an apple rootstock progeny using the Malus Infinium whole genome genotyping array. BMC Genomics (2012) 1.42
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol (2013) 1.41
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol (2004) 1.41
Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol (2010) 1.40
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst (2012) 1.39
Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol (2006) 1.34
An evaluation of the PacBio RS platform for sequencing and de novo assembly of a chloroplast genome. BMC Genomics (2013) 1.33
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Assessing the measure of a new drug: is survival the only thing that matters? J Clin Oncol (2008) 1.30
Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat (2009) 1.30
Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One (2012) 1.30
Synteny conservation between two distantly-related Rosaceae genomes: Prunus (the stone fruits) and Fragaria (the strawberry). BMC Plant Biol (2008) 1.29
An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Stat Med (2007) 1.29
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol (2010) 1.28
Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys (2002) 1.27
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer (2013) 1.25
Predictive biomarker validation in practice: lessons from real trials. Clin Trials (2010) 1.24
Integrating biomarkers in clinical trials. Expert Rev Mol Diagn (2011) 1.24
Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol (2013) 1.22
Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol (2002) 1.22
Biomarkers, subgroup evaluation, and clinical trial design. Discov Med (2012) 1.21
An autotetraploid linkage map of rose (Rosa hybrida) validated using the strawberry (Fragaria vesca) genome sequence. PLoS One (2011) 1.21
FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol (2007) 1.20
Comparative analysis of rosaceous genomes and the reconstruction of a putative ancestral genome for the family. BMC Evol Biol (2011) 1.20
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol (2009) 1.20
Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys (2002) 1.19
Randomized clinical trial of high-dose levamisole combined with 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. Clin Colorectal Cancer (2006) 1.18
Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg (2003) 1.17
A 2-stage phase II design with direct assignment option in stage II for initial marker validation. Clin Cancer Res (2012) 1.14
Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol (2009) 1.14
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. J Clin Oncol (2014) 1.14
Adaptive adjustment of the randomization ratio using historical control data. Clin Trials (2013) 1.14
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a north central cancer treatment group review of 3811 patients, n0144. Clin Colorectal Cancer (2009) 1.13
Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst (2011) 1.12
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep (2013) 1.12
Functional and clinical significance of variants localized to 8q24 in colon cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.11
Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. J Clin Oncol (2014) 1.10
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer (2004) 1.10
Long-term follow-up and individual item analysis of quality of life assessments related to laparoscopic-assisted colectomy in the COST trial 93-46-53 (INT 0146). Ann Surg Oncol (2011) 1.09
Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. J Clin Oncol (2002) 1.09
Prognostic impact of bim, puma, and noxa expression in human colon carcinomas. Clin Cancer Res (2008) 1.08
Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Stat Med (2010) 1.08